Pancreatic Cancer Research

ResearcherBrentwood Biomedical Research InstituteActive in the last 2 years

Mouad Edderkaoui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2549-8242; OpenAlex author ID A5063303902; NIH RePORTER profile ID 8521797. Sources: OpenAlex.

Their work

Papers
33 (first author 5, last author 4)
Trials
0
Grants
1
Labs led
2
Collaborators
83
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper, 1 grant · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 5 papers · 2023: 2 papers · 2024: 4 papers · 2025: 3 papers · 2026: 2 papers

Papers 33

  1. Specific targeting of cancer cell mitochondria with a malaria drug improves pancreatic cancer outcome. Last author DOI 10.1038/s41598-026-66961-9↗
  2. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 Glut… Co-author DOI 10.1038/s43018-026-01225-z↗
  3. Unraveling the hepatoprotective and anti-pancreatic cancer potential of Caralluma europaea: a comprehensive in vivo, in vitro and in silico evidence. Co-author DOI 10.1080/01480545.2024.2402430↗
  4. Significantly higher incidence of circulating fatty objects in portal blood samples compared to peripheral blood samples in patients with pancreatic ductal ade… Co-author DOI 10.3389/fonc.2025.1611872↗
  5. HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. Co-author DOI 10.7150/ijbs.102132↗
  6. Stromal softness confines pancreatic cancer growth through lysosomal-cathepsin mediated YAP1 degradation. Co-author DOI 10.1007/s00018-024-05466-y↗
  7. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.freeradbiomed.2024.01.003↗
  8. Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A Loss and Pancreatic Cancer Aggressiveness. Co-author DOI 10.1016/j.gastha.2024.04.005↗
  9. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  10. Evaluation of the toxicity of Caralluma europaea (C.E) extracts and their effects on apoptosis and chemoresistance in pancreatic cancer cells. Co-author DOI 10.1080/07391102.2022.2135595↗
  11. Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity Co-author DOI 10.21203/rs.3.rs-3647514/v1↗
  12. Novel DZ-SIM Conjugate Targets Cancer Mitochondria and Prolongs Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/adtp.202200021↗
  13. HDAC4 Mediates Smoking-Induced Pancreatic Cancer Metastasis. Last author DOI 10.1097/mpa.0000000000001998↗
  14. Co-Variation of Serum Osteoprotegerin and Pigment-Epithelial Derived Factor as Biomarker of Pancreatic Cancer. Co-author DOI 10.26420/austinjgastroenterol.2022.1118↗
  15. Sequestration of Intestinal Acidic Toxins by Cationic Resin Attenuates Pancreatic Cancer Progression through Promoting Autophagic Flux for YAP Degradation. Co-author DOI 10.3390/cancers14061407↗
  16. Glycogen Synthase Kinase 3β: A True Foe in Pancreatic Cancer. Last author DOI 10.3390/ijms232214133↗
  17. Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001335↗
  18. MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3389/fphys.2019.00147↗
  19. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Co-author DOI 10.1053/j.gastro.2018.08.028↗
  20. Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration. Co-author DOI 10.1016/j.ajpath.2016.09.012↗
  21. Tobacco and alcohol as risk factors for pancreatic cancer. Co-author DOI 10.1016/j.bpg.2017.09.001↗
  22. The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. First author DOI 10.3389/fphys.2017.00381↗
  23. Macrophages and pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2015.11.049↗
  24. HDAC3 mediates smoking-induced pancreatic cancer. Co-author DOI 10.18632/oncotarget.6820↗
  25. What are the macrophages and stellate cells doing in pancreatic adenocarcinoma? First author DOI 10.3389/fphys.2015.00125↗
  26. Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Co-author DOI 10.3389/fphys.2014.00490↗
  27. NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox. Co-author DOI 10.1074/jbc.a110.200063↗
  28. Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells. Co-author DOI 10.1080/01635581.2013.832779↗
  29. Molecular basis for the interplay of apoptosis and proliferation mediated by Bcl-xL:Bim interactions in pancreatic cancer cells. First author DOI 10.1016/j.bbrc.2012.05.032↗
  30. The burning question: why is smoking a risk factor for pancreatic cancer? Last author DOI 10.1016/j.pan.2012.06.002↗
  31. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. First author DOI 10.1053/j.gastro.2011.10.026↗
  32. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. Co-author DOI 10.1111/j.1440-1746.2011.07013.x↗
  33. NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox. Co-author DOI 10.1074/jbc.m110.200063↗

Grants 1

  1. Mediators of pancreatic cancer induction by alcoholic pancreatitis and smoking K01AA019996↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephen Jacob Pandol · 28 shared papers, 2011–2026 · strength 3.52
  2. Omer Hany Miligy Elmadbouh · 7 shared papers, 2022–2026 · strength 1.38
  3. Yan Ou · 4 shared papers, 2022–2026 · strength 0.90
  4. Ruoxiang Wang · 4 shared papers, 2017–2026 · strength 0.79
  5. Neil A. Bhowmick · 4 shared papers, 2018–2026 · strength 0.65
  6. Arsen Osipov · 3 shared papers, 2024–2026 · strength 0.64
  7. Ramachandran Murali · 3 shared papers, 2018–2025 · strength 0.48
  8. Qiang Wang · 4 shared papers, 2017–2024 · strength 0.42
  9. Raul A. Urrutia · 2 shared papers, 2024–2025 · strength 0.42
  10. Dalila Bousta · 2 shared papers, 2023–2025 · strength 0.40
  11. Fatima Ez‐Zahra Amrati · 2 shared papers, 2023–2025 · strength 0.40
  12. Dina Hauptschein · 2 shared papers, 2022–2025 · strength 0.38
  13. Andrew Eugene Hendifar · 2 shared papers, 2023–2026 · strength 0.37
  14. Hayato Muranaka · 2 shared papers, 2023–2026 · strength 0.37
  15. Jun Gong · 2 shared papers, 2023–2026 · strength 0.37
  16. Tianci Zhang · 2 shared papers, 2022–2024 · strength 0.33
  17. Yuan‐Ping Han · 2 shared papers, 2022–2024 · strength 0.33
  18. Guido Eibl · 5 shared papers, 2012–2019 · strength 0.27
  19. Simon K. Lo · 1 shared paper, 2025 · strength 0.23
  20. Rabindra R. Watson · 1 shared paper, 2025 · strength 0.23
  21. Srinivas Gaddam · 1 shared paper, 2025 · strength 0.23
  22. Aida Habtezion · 3 shared papers, 2016–2018 · strength 0.21
  23. Tao Liu · 1 shared paper, 2024 · strength 0.21
  24. Wei Jie Zhou · 1 shared paper, 2024 · strength 0.21
  25. David W. Dawson · 2 shared papers, 2012–2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.